Immunotherapeutic approaches to inflammatory bowel diseases

Expert Opinion on Biological Therapy

Volumn 1, Issue 3, 2001, Pages 455-466

  Holtmann, Martin H ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Biological drugs; Experimental therapy; Immunomodulation; Inflammatory bowel disease

Indexed keywords

ANIMAL; ENTERITIS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; REVIEW;

ANIMAL; HUMAN; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; MICE;

EID: 0035346851     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.3.455     Document Type: Article

References (82)

1. DUCHMANN R, ZEITZ M: Crohn's disease. In: Handbook of mucosal immunology. Ogra P, Strober W (EdsJ, Academic Press, San Diego, (1999):1055
2. KORNBLUTH A, SALOMON P, SACHAR: Crohn's disease. In: Gastronitestinal disease. Pathophysiolgy, diagnosis, management. Fortran J, Sleisinger M (Eds.) Saunders, Philadelphia, DB (1995):1270.
3. DUCHMANN R, MAY E, HEIKE M et al.: T cell specificity and cross reactivity toweard cntcrobacteria, bacteroides, bifidobacterium and antigens from resident intestinal flora in humans. Gut (1999) 44(6):812-818. •• One of the most important works supporting the concept of luminal antigens triggering intestinal inflammation.
4. NAGLER-ANDERSON C: Tolerance and immunity in the intestinal immune system. Crit. Rev. Immunol. (2000) 20:103-120.
5. MONTELEONE G, BIANCONE L, MARASCO R et al.: Interleukin-12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology (1997) 112:1169. • This work represents a major contribution to the concept that IL-12 is a key cytokine in CD.
6. + lamina propria (LP) lymphocyte secretion profiles in inflammatory bowel disease. J. Immunol. (1996) 157:1261.
7. PLEVY SE, LANDERS CJ, PREHN J et al.-. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. (1997) 159:6276-6282.
8. AUTSCHBACH F, SCHÜRMANN G, QIAO L, MERZ H et al.: Cytokine messenger RNA expression and proliferation status of intestinal mononuclcar cells in noninflamed gut and Crohn's disease. Vircbows Arch. (1995) 426:51.
9. + lamina propria (LP) lymphokine secretion profiles in Inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. (1996) 157:1261-1270.
10. BOIRIVANT M, FUSS IJ, CHU A, STROBER W: Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp. Med. (1998) 188:1929-1939.
11. SCHREIBER S, HEINIG T, THIELE HG, RAEDLER A: Immunorcgulatory role of interleukhi-10 in patients with inflammatory bowel diseases. Gastroenterology (1995) 108:1434-1434.
12. NEURATH MF, PETTERSSON S, MEYER ZUM BUSCHENFELDE KH, STROBER W: Local administration of antisense phosphorothioatc oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis In mice. Nat. Med. (1996) 2(9):998-1004.
13. AUPHAN N, DIDONATO JA, ROSETTE C, HELMBERG A, KARIN M: Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IkB synthesis. Science (1995) 270:286-290.
14. AUTSCHBACH F, BRAUNSTEIN J, HELMKE B et ah In situ expression of intcrleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am. J. Path. (1998) 153:121.
15. WATANABE M, UENO Y, YAJIMA T étal.: Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. Clin. Invest. (1995) 95:2945-2953.
16. POUPON V, CERF-BENSUSSAN N: Adhesion molecules on mucosal lymphocytes. In: Mticosal Immmimology (2nd Edition). Ogra PL, Bienenstock I, Strober W (Eds.), Academic Press, San Diego, (1999):523.
17. CHRIST A, STEVENS A, KOEPPEN H et al: An interleukin 12-related cytokine is up-regulated in ulcerative colitis but not in Crohn's disease. Gastroenterology (1998) 115:307.
18. NEURATH MF, FUSS I, KELSALL BL, STUBER E, STROBER W: Antibodies to II.-12 abrogate established experimental colitis in mice. J Exp. Med. (1995) 182:1280.
19. VAN DEVENTER SJ. Tumour necrosis factor and Crohn's disease. Gut (1997) 40:443-448.
20. ELSON CO, SARTOR RB, TENNYSON GS, RIDDELL RH: Experimental models of inflammatory bowel disease. Gastroenterology(1995) 109:1344-1367.
21. KÜHN R, LÖHLER J, RENNICK D, RAJFAVSKI K, MÜLLER W: Interleukin-10 deficient mice develop chronic entcrocolitis. Cell(1993) 75:263-274.
22. + T cells Induce or protect from chronic intestinal inflammation in C. B-17 seid mice. Int. Immunol. (1993) 5:1461-1471.
23. OKAYASU I, HATAKEYAMA S, YAMADA M, OHKUSA T, INAGAKI Y, NAKAYA R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology (1990) 98:1859-1866.
24. +T cells. Immunlty(1994) 1:553-562.
25. high T Cells. J. Exp. Med. (1999) 190:1479-1491.
26. NEURATH MF, FUSS I, PASPARAKIS M et al: Predominant pathogenelc role of tumor necrosis factor hi experimental colitis in mice. Eur.J. Immunol. (1997) 27:17643-17650.
27. KOJOUHAROFF G, HANS W, OBERMEIER F et al: Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dcxtran sulphate sodium-induced colitis hi mice. Clin. Exp. Immunol. (1997) 107(2):353-358.
28. ATREYA R, MUDTER J, FINOTTO S et al: MF Blockade of interleukin 6 trans signaling suppresses T-ccll resistance against apoptosis hi chronic intestinal inflammation: evidence hi crohn disease and experimental colitis in vivo. Nat. Med. (2000) 6(5):583-588.
29. MOMBAERTS P, MIZOGUCHI E, GRUSBY MJ, GLIMCHER LH, BHAN AK, TONEGAWA S: Spontaneous development of Inflammatory bowel disease hi T cell receptor mutant mice. Cell (1993) 75:275-282.
30. SADLACK B, MERZ H, SCHORLE H, SCHIMPL A, FELLER AC, HORAK I: Ulceraüve colitis-like disease with a disrupted interleukin 2 gene. Cell (1993) 75:253-261.
31. WATANABE M, UENO Y, YAJIMA T et al: Interleukin 7 transgenic mice develop chronic colitis with decreased interleuin 7 protein accumulation hi the colonie mucosa. J Exp. Med. (1998) 187:389-402.
32. LICHTIGER S, PRESENT DH, KORNBLUTH A et al: Cyclosporine hi severe ulcerative colitis refractory to steroid therapy. N. Engl.J. Med. (1994) 330:1841-1845.
33. YIN MJ, YAMAMOTO Y, GAYNOR RB: The anti-inflammatory agents aspirin and salicylatc inhibit the activity of I(kappa)B kinase-beta. Nature (1998) 396:77-80.
34. BROOKE BN, HOFFMANN DC, SWARBRICK ET: Azathioprine for Crohn's disease. Lancet (1969) 2:612-614.
35. BROWN CH, ACHKAR E: Azathioprine therapy for inflammatory bowel disease. A preliminary report. Am.J. Gastroenterol. (1979) 54:363-377.
36. HILDNER KE et al.-. Azathioprine, mycophenolate mofetil and mcthotrexate specifically modulate cytokine production by T cells. Ann. NYAcad. Sci. USA (1998) 85(9):204-207.
37. LENNARD L, HARRINGTON CL, WOOD M, MADDOCKS JL: Metabolism of azathloprine to 6-thioguaninc nuclcotides in patients with pemphigus vulgaris. Br.J. Clin. Pbannacol. (1987) 23:229-233.
38. LENNARD L, KEEN D, LILLEYMAN JS: Oral 6-mcrcaptopurinc hi childhood leukemia: parent drug pharmocokinetics and active metabolite concentrations, din. Pbannacol. Ther. (1986) 40:287-292.
39. NEURATH MF et al.: Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen induced arthritis (CIA): a mechanism for mcthotrexate-mediatcd immunosuppression. Clin. Exp. Immunol. (1999) 115:42-55.
40. HILDNER KE et al.: TNF production by cell receptorprimed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin. Exp. Immunol. (1999) 118:137-146.
41. FEAGAN G et al.: Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. M Engl.J.Med.(.1995) 332:292-297.
42. OREN R et al.: Methotrexate hi chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am.J. Gastroenterol. (1997) 92:2203-2209.
43. OREN R et al.: Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology (1996) 110:1416-1421.
44. NEURATH MF et al.: Randomized trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Cur (1999) 44:625-628.
45. FLORIN TH, ROBERTS RK, WATSON MR, RADFORT-SMITH GL: Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF). Aust. Z.J. Med. (1998) 28(3):344-345.
46. CASH JM, HOFFMAN GS: Immunomodulating pharmaceuticals. In: Clinical Immunology. Rich RR (Ed.), St. Louis, Mosby (1999):1980-1992.
47. BRYNSKOV J et al: A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N. Engl. J. Med. (1989) 321: 845-850.
48. JEWELL DP, TRUELOVE SC: Azathioprine in ulcerative colitis: final repaort on controlled therapeutic trial. BMJ (.1974) 4:627-630.
49. STANGE EF, MODIGLIANI R, PENA AS, WOOD AJ, FEUTREN G, SMITH PR: European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. Gastroenterology (1995) 109:774-782.
50. FELLERMANN K, LUDWIG D, STAHL M, DAVID-WALEK T, STANGE EF: Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am. J. Gastroenterol. (1998) 93:1860-1866.
51. KNIGHT DM, TRINH H, LE J et al.-. Construction and initial characterization of a mouse-human chimcric anti-TNF antibody. Mol. Immimol. (1993) 3:1443-1453.
52. SCALLON BJ, MOORE MA, TRINH H, KNIGHT DM, GHRAYEB J: Chimeric anti-TNF-a monoclonal antibody cA2 binds recombinant transmembranc TNF-cx and activates immune effector functions. Çytokine (1995) 7:15-25
53. SIEGEL SA, SHEALY DJ, NAKADA MT et al.: The mouse/human chimcric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachcxia andTNF lethality n vivo. Cytokine(.l995) 7:15-25.
54. VAN DER POLL, LEVI M, DULLER HR et al.: Fibrinoh/tic response to tumor necrosis factor in healthy subjects. J. Exp. Med. (1991) 174:729-732.
55. TARGAN SR, HANAUER SB, VAN DEVENTER SJH et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N. Etigl.J. Med. (1997) 337:1029.
56. PRESENT DH, RUTGEERTS P, TARGAN S eta!.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl.J. Med. (1999) 340:1398-1405.
57. RUTGEERTS P et al: Efficacy and safety of retrcatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroentero/cgy(1999) 117:761-769.
58. BICKSTON SJ, LICHTENSTEIN GR, ARSENEAU KO, COHEN RB, COMINELLI F: The relationship between inflixmimab treatment and h/mphoma in Crohn's disease. Gastmenterology(.1999) 117:1433-1437.
59. SANDBORN WJ, HANAUER SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm. Bou-elDis. (1999) 5:119-133.
60. EVANS RC, CLARKE L, HEATH P, STEPHENS, MORRIS AI, RHODES JM: Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Ailment. Pbarmacol. ner. (1997) 11:1031-1035.
61. STACK WA, MANN SD, ROY AJ et al: Randomized controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet (.1997) 22:521-524.
62. MOREIRA AL, SAMPAIO EP, ZMUIDZINAS A, FRINDT P, SMITH KA, KAPLAN G: Thalidomidc exerts ist inhibitory action on tumor necrosis factor- by enhancing messenger RNA degradation. J. Exp. Med. (1993) 177:1675-1680.
63. VASILIAUSKAS EA, KAM LY, ABREU-MARTIN MT et al: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastmeiitemlogy(1999) 117:1278-1287.
64. EHRENPREIS ED, KANE SV, COHEN LB, COHEN RD, HANAUER SB: Thalidomidc therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 117:1271-1277.
65. REIMUND JM, DUMONT S, MULLER CD et al: In vitro effects of oxpentifylline on inflammatory cytokinc release in patients with inflammatory bowel disease. Gut (.1997) 40:475-480.
66. BAUDITZ J, HAEMLING J, ORTNER M, LOCHS H, RAEDLER A, SCHREIBER S: Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dcpendcnd chronic active Crohn's disease. Gut (.1997) 40:470-474.
67. BLACK RA, RAUCH CT, KOZLOSKY CJ étal: A mctalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 385:729.
68. WILLIAMS LM, GIBBONS DL, GEARING A, MAINI RN, FELDMANN M, BRENNAN FM: Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing hi RA synovial membrane cell cultures. J. din. Invest. (1996) 97:2833-2841.
69. TEPLER I, ELIAS L, SMITH JW II et al: A randomized placebo-controlled trical of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood (.1996) 87:3607-3614.
70. QIU BS, PFEIFFER CJ, KEITH JC Jr.: Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig. Dis. Sei. (1996) 41:1625-1630.
71. SANDS BE, BANK S, SNINSKY ÇA et a!.: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastmentemlogy (1999) 117:58-64.
72. VAN DEVENTER SJ, ELSON CO, FEDORAK RN: Multiple doses of intravenous interlcukin 10 in steroidrefractory Crohn's disease. Crohn's Disease Study Group. GastroetJteroIogy(.1997) 113:383-389.
73. HAMAMOTO N, MAEMURA K, HIRATA I, MURANO M, SASAKI S, KATSU K: Inhibition of dextran sulphate sodium (DSS)-induccd colitis in mice intracolonicaUy administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1), or intercellular adhesion moleculc-1 (ICAM-1). Clin. Exp. Immunol (1999) 117:462-468.
74. SORIANO A, SALA A, SALAS A et al: VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockadc ameliorates DSS-induced colitis in mice. Lab. Invest. (2000) 80:1541-1551.
75. KRIEGELSTEIN CF, ANTHONI C, LAUKOTTER MG et al: Effect of anti-CDllb (alphaM-MAC-1) and anU-CD54 (ICAM-1) monoclonal antibodies on indomethacin induced chronic Ueitis in rats. Int. J. Colorectal. Dis. (1999) 14:219-223.
76. SALAS A, SANS M, SORIANO A et al: Heparin attenuates TNF-alpha induced inflammatory response thorugh a CDllb dependent mechanism. Gut (2000) 47:88-96.
77. YACYSHYN DR, BOWEN-YACYSHYN MB, JEWELL L et al: A placebo-controlled trial of ICAM-1 antiscnsc oligonuclcotidc in the treatment of Crohn's disease. Gastn>entemhg>'(.1998) 114:1133-1142.
78. FUSS IJ, MARTH T, NEURATH MF, PEARLSTEIN GR, JAIN A, STROBE R: Anti-interleukin 12 treatment regulates apoptosis of Thl T-cclls in experimental colitis in mice. Gastmeiitemlogy(.1999) 117(5):1078-1088.
79. SUMER N, PALABIYIKOGLU M: Induction of remission by intcrfcron-alpha in patients with chronic active ulcerativc colitis. Etir. J. Gastroenteml. Hepatol. (1999) 7:597.
80. wrrnG BM, JOHANSSON B, ZOLLER M, SCHWARZLER c, GUNTHERT U: Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (DC44v7). J. Exp. Med. (2000) 191:2053-2064.
81. WITTIG B, SCHWARZLER C, FOHR N, GUNTHERT U, ZOLLER M: Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J. Immunol. (1998) 161:1069-1073.
82. WIRTZ S, GALLE PR, NEURATH MF: Efficient gene delivery to the inflamed colon by local administration of rccombinant adenoviruses with normal or modified fibre structure. Gut (1999) 6:800-807. Martin H Holtmann 1, Peter R Galle & Markus F Neuiath 1 Author for correspondence